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a b s t r a c t 
Ferroptosis is a recently discovered form of iron-dependent regulated cell death (RCD) that occurs via per- 
oxidation of phospholipids containing polyunsaturated fatty acid (PUFA) moieties. Activating this form of 
cell death is an emerging strategy in cancer treatment. Because multiple pathways and molecular species 
contribute to the ferroptotic process, predicting which tumors will be sensitive to ferroptosis is a chal- 
lenge. We thus develop a mathematical model of several critical pathways to ferroptosis in order to per- 
form a systems-level analysis of the process. We show that sensitivity to ferroptosis depends on the 
activity of multiple upstream cascades, including PUFA incorporation into the phospholipid membrane, 
and the balance between levels of pro-oxidant factors (reactive oxygen species, lipoxogynases) and an- 
tioxidant factors (GPX4). We perform a systems-level analysis of ferroptosis sensitivity as an outcome 
of five input variables (ACSL4, SCD1, ferroportin, transferrin receptor, and p53) and organize the resulting 
simulations into ‘high’ and ‘low’ ferroptosis sensitivity groups. We make a novel prediction corresponding 
to the combinatorial requirements of ferroptosis sensitivity to SCD1 and ACSL4 activity. To validate our 
prediction, we model the ferroptotic response of an ovarian cancer stem cell line following single- and 
double-knockdown of SCD1 and ACSL4. We find that the experimental outcomes are consistent with our 
simulated predictions. This work suggests that a systems-level approach is beneficial for understanding 
the complex combined effects of ferroptotic input, and in predicting cancer susceptibility to ferroptosis. 
© 2020 The Authors. Published by Elsevier Ltd. 
This is an open access article under the CC BY-NC-ND license. 
( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 
1. Introduction 
Ferroptosis is a recently discovered form of regulated cell 
death (RCD) that is triggered by iron-dependent lipid perox- 
idation ( Stockwell et al., 2017 ). Ferroptosis is a member of a 
broader family of RCD pathways that also includes necroptosis, 
parthanatos, pyroptosis, apoptosis, and others ( Stockwell et al., 
2017 ; Vandenabeele et al., 2010 ; Conrad et al., 2016 ; Vanden 
Berghe et al., 2014 ; Galluzzi et al., 2018 ). Critical features of RCD 
processes include control by specific intrinsic cellular mechanisms, 
resulting in susceptibility of RCD to pharmacologic and genetic 
modulation. This distinguishes RCD from accidental death caused 
by severe chemical or mechanical insults ( Vandenabeele et al., 
2010 ; Conrad et al., 2016 ; Vanden Berghe et al., 2014 ). Different 
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types of RCD serve complementary roles during homeostatic, 
developmental, and pathogenic processes. For example, apoptosis, 
perhaps the best-studied mechanism of RCD, is programmed to oc- 
cur in normal physiological contexts such as development ( Galluzzi 
et al., 2018 ). RCD can also serve as a form of intercellular commu- 
nication: release of oxidized lipids resulting from a cell undergoing 
ferroptosis may serve to promote ferroptosis and other forms of 
cell death in nearby cells ( Conrad et al., 2016 ). In addition, cellular 
internal state can drive a cell to undergo one vs. another form of 
RCD, as exemplified by the influence of autophagy, the process of 
regulated lysosomal degradation of cytoplasmic components, on 
the cellular decision to undergo RCD ( Loos and Engelbrecht, 2009 ; 
Napoletano et al., 2019 ; Hou et al., 2016 ). Therefore, development 
of a systems-level understanding of ferroptosis becomes critical 
not only for understanding and predicting the process itself, but 
also for developing more comprehensive models of cell survival 
and death under a wide range of conditions. 
https://doi.org/10.1016/j.jtbi.2020.110222 
0022-5193/© 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license. ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 
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Both intentional induction of ferroptosis and its prevention are 
the focus of current drug development effort s. Thus, ferroptosis 
inhibitors are being considered as agents for the treatment of 
neurodegenerative disease ( Angeli et al., 2017 ; Wu et al., 2018 ); 
conversely, substantial effort is being directed at the discovery of 
ferroptosis-inducing agents to treat cancer ( Stockwell et al., 2017 ; 
Shen et al., 2018 ). Further, recent work suggests that existing anti- 
cancer agents such as cisplatin and sorafinib trigger ferroptotic 
pathways ( Guo et al., 2018 ; Lachaier et al., 2014a ; Lachaier et al., 
2014b ). The finding that drug-tolerant “persister” cells are partic- 
ularly vulnerable to ferroptosis inducers has further heightened 
interest in ferroptosis as a potential mechanism for treating drug 
resistant cancers. Ovarian cancer, a malignancy in which successful 
treatment is frequently thwarted by the emergence of drug resis- 
tance ( Agarwal and Kaye, 2003 ; Norouzi-Barough et al., 2018 ), may 
be an ideal candidate for such an approach. Indeed, our laboratory 
has shown that ovarian cancer cells are exquisitely sensitive to 
ferroptosis inducers in vitro and in vivo ( Basuli et al., 2017 ). 
Sensitivity to ferroptosis is complex and depends on multiple 
interacting molecular components. Here, we use mathematical 
modeling to synthesize currently understood ferroptotic processes 
into a dynamic, predictive model to better understand how 
ferroptotic processes can be harnessed for anti-cancer therapy. 
Such a model can be used to predict the cellular phenotype(s) 
that are optimal for ferroptotic sensitivity, as well as the relative 
contributions of molecular species and submodules in the net- 
work to the ferroptotic response. Indeed, mathematical models 
of apoptosis have helped to answer a number of outstanding 
biological questions with respect to this form of regulated cell 
death ( Schleich and Lavrik, 2013 ), as well as to develop optimized 
protocols for oncotherapy ( Panetta and Fister, 20 0 0 ; Konstorum et 
al., 2017 ). Models that explore the influence of autophagy on the 
cell decision process to undergo apoptosis ( Tavassoly et al., 2015 ; 
Liu, 2017 ), and the cell decision process to survive or undergo 
apoptosis or necrotic cell death ( Calzone et al., 2010 ), provide 
examples of how integration of different models for cell death and 
survival can be accomplished. 
Kagan et al. (2017) recently developed a continuum model 
for ferroptosis with a focus on biochemical cascades occurring 
in the phosphatidylethanolamine (PE) class of phospholipids. 
While that model provides an excellent synthesis of specific 
processes involved in arachidonic acid metabolism, lipoxogynase 
activity, and GPX4 regulation, it excludes contributions of iron, 
lipid desaturases, and additional components of import to the 
lipid peroxidation processes involved in ferroptosis. Agmon et al. 
(2018) performed molecular dynamics simulations of membranes 
with compositions relevant to ferroptotic sensitivity, and showed 
how the biophysical properties of membranes are altered under 
ferroptotic-competent lipid compositions. 
We developed our model to answer systems-level questions 
regarding ferroptosis sensitivity and its interdependence on the co- 
ordinated activities of several distinct molecular species that have 
been identified as central to the ferroptotic signaling pathway, with 
a focus on species that have been found important for the lipid 
peroxidation processes critically involved in ferroptosis ( Dixon and 
Stockwell, 2014 ; Yang and Stockwell, 2016 ; Stockwell et al., 2017 ). 
We use a multistate discrete modeling approach to emphasize 
qualitative properties of signaling cascades relevant to ferroptosis. 
The discrete modeling approach allows us to investigate the rel- 
ative importance of different drivers of ferroptosis using a wider 
range of data than would be available for a detailed kinetic model 
of the system. Discrete models can provide a mechanistic, systems- 
level, understanding of a process that can serve to better focus 
future detailed kinetic modeling. Discrete models have been used 
successfully to model a variety of important processes in cancer, 
including cell cycle progression driven by PI3K ( Sizek et al., 2019 ), 
the topography of epithelial-mesenchymal transitions ( Font-Clos et 
al., 2018 ), and transcription factor networks in small cell lung can- 
cer ( Sizek et al., 2019 ; Font-Clos et al., 2018 ; Udyavar et al., 2017 ). 
Using this model, we connect signaling modules related to 
phosholipid precursor processing, phospholipid peroxidation, ROS 
signaling and generation, and GPX4 activity, and demonstrate 
how each contributes to ferroptosis sensitivity. We demonstrate 
how the model can be used to make novel predictions about the 
combined impact of multiple perturbations on the response to 
ferroptosis, and provide a proof-of-principle experimental valida- 
tion of these predictions. We provide source-code for the model 
in ( Konstorum, 2020 ). 
2. Results 
2.1. Model overview 
Using the available literature, we developed a logic-based mul- 
tistate model for the intracellular ferroptotic process, with a focus 
on pro- and anti-oxidant actors in lipid peroxidation ( Fig. 1 ). All 
model components were chosen such that they were found to be 
central components in pro-and anti-oxidant processes in ferropto- 
sis, and each individually was identified to play a promotional or 
inhibitory role in ferroptosis. The goal for model development was 
to investigate how the activity of these actors modifies ferroptotic 
sensitivity in a systems analysis. We provide an overview of how 
model components (underlined) were chosen, and refer the reader 
to Section 4 (Methods) for a more detailed description of indi- 
vidual component biology, evidence of importance for ferroptosis, 
and mechanism of model incorporation. 
Ferroptosis is characterized by iron -dependent lipid peroxida- 
tion that occurs in the presence of agents, such as erastin or RSL3 , 
that inhibit counteractive antioxidant processes ( Dixon et al., 2012 ). 
An antioxidant process found to be critical in protection from fer- 
roptosis is mediated by the lipid peroxidase GPX4 ( Yang et al., 
2014 ). In order for ferroptosis to proceed, phospholipid molecules 
containing polyunsaturated fatty acids ( LH-P ) are generated from 
acetylated polyunsaturated fatty acids ( PUFA-CoA ) in a process 
that depends on the presence of the LPCAT3 enzyme (and relative 
absence of monounsaturated fatty acids, MUFAs , which can be pro- 
duced by desaturation by SCD1 of saturated fatty acids ( SFAs )). The 
PUFA-CoA moieties are produced from membrane polyunsaturated 
fatty acids (PUFAs) such as Arachidonic Acid ( AA ) by acyl-CoA 
synthetases such as ACSL4 , an enzyme whose activity has been 
found to be critical for ferroptosis sensitivity ( Doll et al., 2017 ; 
Dixon et al., 2015 ). The LH-P are oxidized to lipid hydroperoxides 
( LOOH ) and eventually to lipid radicals (LO •) - which contribute 
to the initiation of ferroptosis - by reactive oxygen species ( ROS s) 
and/or lipid peroxidating enzymes such as ALOX15 , which act as a 
trigger for cell death ( Feng and Stockwell, 2018 ). Presence of GPX4 
can mitigate this process since it can reduce LOOH to LOH , thereby 
preventing its further oxidation. Iron , which promotes the forma- 
tion of ROS through Fenton chemistry, is also required for ferrop- 
tosis ( Dixon et al., 2012 ). Cellular levels of iron are dependent on 
several proteins, notably TFR1 , an iron importer that is generally 
upregulated in cancer, and ferroportin ( Fptn ), an iron efflux pump 
that is downregulated in cancer ( Torti and Torti, 2011 ; Torti and 
Torti, 2013 ; Torti et al., 2018 ). Additionally, p53 can act in two ways 
to promote ferroptosis: by increasing ALOX15 ( Ou et al., 2016 ), 
and inhibiting SLC7A11 , a component of the cystine/glutamate 
antiporter system x c 
− (cystine is a necessary precursor for GPX4 
production). 
The model is informed by results from multiple cell types 
and over 25 publications (see Methods for full model details). 
Each molecular species can take on a value of ‘low’ (0), ‘medium’ 
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Fig. 1. Diagrammatic overview of the multistate model for ferroptosis. Input parameters are model elements that do not change during the course of the simulation (blue 
outline; dashed line beneath), model variables on the other hand will change concentrations until reaching a steady state (blue outline). Molecular species that are implicitly 
included in the model but not simulated are also shown (black outline) as well as ferroptosis inducers (green outline). AA: arachidonic acid, LH-P: phospholipid conjugated 
to polyunsaturated fatty acid, LIP: labile iron pool, LOOH: lipid hydroperoxide, LO 
•
: peroxide radical, LOH: redox-inert alcohol, MUFA: monounsaturated fatty acids, PL: 
phospholipid, PUFA-CoA: acetylated polyunsaturated fatty acids, ROS: reactive oxygen species, system x c 
−: cystine/glutamate transporter, SFA: saturated fatty acids. 
(1), or ‘high’ (2) activity/expression. Such a coarse-grained model 
can be used to understand qualitative characteristics of a system 
without detailed knowledge of biochemical rate parameters. Such 
models, which can specify functions using logical rule gates or 
transition tables, have been used successfully as described in the 
Introduction, as well in further studies such as to obtain novel 
biological understanding in cancer cell metabolism ( Chifman et al., 
2017 ), T cell receptor signaling ( Saez-Rodriguez et al., 2007 ), innate 
immune response ( Dimitrova et al., 2018 ), and a variety of other 
biochemical networks ( Morris et al., 2010 ). 
Initial conditions for the model are set as described in the 
Supplementary Information, Section S1 and Table S1. We note that 
simulation steady states do not depend on the initial conditions. 
The settings for the input parameters SCD, TFRC, Fptn, p53, and 
ACSL4 are all set to medium except for ACSL4, which is set to 
‘high’. The latter condition is set since our simulations showed 
that a high ACSL4 is required to achieve a maximal ferroptotic 
response under any conditions of the other input variables. Other 
levels of ACSL4 and the other input variables are explored in 
Section 2.3.2 . Further details on initial conditions for the model 
variables and input parameters are found in the Supplementary 
Information, Section S1. Full source-code for the model can be 
found in ( Konstorum, 2020 ) 
2.2. Response to ferroptosis inducers 
We consider the steady state reached by the cells in our 
simulation with and without ferroptosis stimulation by erastin 
or RSL3, two small molecules specifically designed to induce 
ferroptosis that are widely used in the literature ( Stockwell et al., 
2017 ; Dixon et al., 2012 ) ( Fig. 2 ). We observe that without fer- 
roptosis induction, the cell has a high level of PUFA precursors 
for incorporation into phospholipids (PUFA-CoA), and a moderate 
incorporation of these moieties (LH-P), as well as moderate levels 
of hydroperoxides (LOOH). MUFA and LPCAT3 levels are moderate, 
as well as ROS. GPX4, SLC7A11, and ALOX15 are high. Importantly, 
although there are moderate levels of LOOH, there are low levels 
of peroxide radicals (LO •), which can lead to ferroptosis. One can 
consider such a cell primed for ferroptosis due to the presence of 
LOOH and oxidizers ALOX15 and ROS. The high levels of GPX4 pre- 
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Fig. 2. Addition of erastin or RSL3 in the baseline model stimulates a ferroptotic response. Steady state values of baseline model variables are shown (a) without and (b) 
with addition of the ferroptosis-inducers erastin or RSL3. Note that only SLC7A11 responds differently to erastin (no change) vs. RSL3 (lowered). Variables in gray (‘Input’) 
are external, and thus are set at time t = 0 and stay constant throughout the course of the simulations. The remainder of the variables are classified by types of molecular 
species or mode of action. 
vent the cell from undergoing ferroptosis. Upon addition of erastin 
or RSL3, GPX4 levels are reduced, and we observe the appearance 
of moderate levels of ferroptosis via LO • ( Fig. 2 b). Note that erastin 
acts by inhibiting SLC7A11, which decreases availability of cysteine 
substrate for production of GSH, a co-factor required for GPX4 
activity, whereas RSL3 inhibits GPX4 directly, hence SLC7A11 levels 
are still high in the RSL3 + cell. Thus the model accurately captures 
basic features of the ferroptotic response, an important first step 
towards its use for elucidating novel systems-level requirements 
for ferroptosis. 
2.3. In silico system perturbation 
2.3.1. Single perturbation: ACSL4 
To test the model, we first performed a simple in silico pertur- 
bation that mimics an experiment with a known outcome. ACSL4 
inhibition prevents ferroptosis (Doll et al., 2017). We use RSL3 as 
our ferroptosis-initiator in the model, following Doll et al. (2017). 
We observe that, compared to control baseline ( Fig. 2 a), in the 
ACSL4 knock-out model ( Fig. 3 a) there is low incorporation of PU- 
FAs into phospholipids, and thus less peroxidated phospholipids. 
Even with the addition of the GPX4 inhibitor RSL3 ( Fig. 3 b), we 
do not see an increase in peroxidated phospholipids because their 
precursors are not available – thus reproducing the findings of 
Doll et al. (2017). 
2.3.2. Systems biology of ferroptosis 
To more comprehensively understand how combinations of 
perturbations of system variables will impact ferroptotic response, 
we simulated the effect of all combinations of the input variables 
(3 5 = 243) on system behavior without or with addition of a fer- 
roptotic agent ( Fig. 4 ). We sort the perturbations by (1) decreasing 
LO • value in the erastin + treatment group and (2) for each LO •
value-subgroup in the erastin treatment group, increasing LO •
value in the control treatment group. In this way, the patterns of 
the input variables that lead to the maximal ferroptotic response 
in each subgroup are easily identifiable. A comprehensive set of 
simulations is necessary to tease out the inter-related impact of 
the input variables on ferroptosis sensitivity, since the value of 
any one input variable is usually not, alone, predictive of ferrop- 
totic response when all other input variables are allowed to vary 
(Supplementary Information, Section S2). 
We analyze the output of the respective high and low fer- 
roptotic response subgroups, and include an analysis of the 
intermediate ferroptotic response in the Supplementary Informa- 
tion (Section S3). We conclude this subsection with a summary of 
the results in the form of a rule-based ‘algorithm’ for the cell that 
allows for a signature-based analysis of the input variables with 
respect to outcome in ferroptosis sensitivity. 
2.3.2.1. High ferroptotic response. The high ferroptotic response 
corresponds to ~6.17% of the input conditions, making it the most 
rare outcome. We note that for the cell to achieve a high ferrop- 
totic response with erastin treatment, ACSL4 must be at its highest 
value, and SCD1 at its lowest value ( Fig. 5 ). This combination 
yields maximal PUFA levels (due to high ACSL4) and maximal LH 
levels (due high ACSL4 and low SCD1/MUFA). While we observe 
high PUFA and LH in a small subset of low-ferroptotic response 
signatures ( Fig. 6 ), only the high ferroptotic response signatures 
also have high LOOH, priming them for generating LO • in the 
absence of GPX4. The first peroxidation step is achieved by ROSs 
and/or ALOX15, and we see that ALOX15 and ROS levels are never 
low in the high ferroptotic signature cells. Additionally, for the 
cells to be sensitive to ferroptotic agents, p53 must be either 
at low or medium levels, otherwise SLC7A11, and hence GPX4 
activity, is dampened, allowing for high LO • to be generated even 
in the control-treated cells. This may explain why results of p53 
inhibition in the literature are varied: when p53 is lowered below 
maximal level, other factors contribute and may even predominate 
in determining ferroptosis sensitivity. This may be an interesting 
direction to pursue with respect to developing a more in-depth, 
kinetic model focusing on p53 in ferroptosis in order to further 
understand how this interplay impacts ferroptosis sensitivity. 
2.3.2.2. Non-responsive ferroptosis cases. We note that the no 
ferroptosis/non-responsive cases, which make up ~71.61% of the 
responses ( Fig. 6 ), include a wide range of input variable values, 
but they all share one feature: there is no LOOH present in all 
the cases, whereas LOOH is at intermediate or high levels in the 
remainder of the simulations ( Fig. 4 ). As can be observed in Fig. 1 , 
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Fig. 3. Effect of ACSL4 knock-out on model behavior (a) without and (b) with addition of RSL3. 
Fig. 4. Ferroptosis model output with all combinations of input conditions, sorted by ferroptotic response. 
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Fig. 5. Ferroptosis model output with all combinations of input conditions, sorted by ferroptotic response, displaying high ferroptosis after erastin treatment. 
LOOH provides the initial substrate for lipid peroxidation (another 
way to consider this is that LOOH is upstream to LO •, the peroxide 
radical that leads to ferroptosis). As can be observed from the 
simulations, and intuited from the diagram in Fig. 1 , LOOH is thus 
necessary (but not sufficient) for cellular ferroptotic sensitivity. 
With no substrate for pro- or anti-oxidant activity, ferroptosis 
cannot be induced. As evidenced here, lack of LOOH can be 
induced by a large number of combinations of input conditions. 
Nevertheless, we do see certain conditions emerge that result in 
non-responsiveness: ACSL4, which catalyzes conversion of AA to 
PUFA-CoA, is necessary (but not sufficient) for production of LOOH. 
Therefore, all conditions with no ACSL4, regardless of the other in- 
put variables, are identified as non-responsive. Indeed, experiments 
in Section 2.4 bear out this observation for a subset of conditions. 
2.3.2.3. A rule-based ‘algorithm’ for cellular sensitivity to ferroptosis. 
We can summarize the results of the systems analysis using a rule- 
based approach for the input variable levels ( Fig. 7 ). These rules 
can be deduced from Figs. 4–6 , Methods ( Section 4.2 ), and Figure 
S2. This approach allows for an analysis akin to a ‘gene-signature’ 
approach to determine ferroptosis sensitivity, as well as succinctly 
summarizes the various dependencies that the cell requires to 
initiate ferroptosis either with or without addition of a ferroptotic 
agent. For example, provided levels of input variables are available, 
one can predict whether a cell with high levels of PUFA-containing 
phospholipids (LOOH) will undergo spontaneous ferroptosis by 
observing the activity of p53 in the cell. Alternatively, a cell with 
a combination of input variables that results in moderate LOOH, 
but not high ROS levels, will not undergo spontaneous ferroptosis 
even under high levels of p53. Much of the intuition surrounding 
the rules in Fig. 7 can be found in the discussion contained within 
Sections 2.3.2.1 and 2.3.2.2 . We consider this cellular ‘algorithm’ 
for ferroptosis sensitivity as a first approach towards considering 
what gene signatures may emerge as predictive for ferroptosis 
sensitivity in a translational setting. 
2.4. Predicting and testing the response of an ovarian cancer stem 
cell line to ferroptotic agents 
We use our model to predict and then experimentally test 
the response of an ovarian cancer stem cell line to ferroptotic 
agents. FT-t cells are a model of high-grade serous ovarian cancer 
(HGSOC) stem cells that were derived from primary culture of 
fallopian tube stem cells (considered to be one of the major cells 
of origin for HGSOC ( Kim et al., 2018 )) via immortalization and 
transformation with h-TERT, SV40 large T antigen, and c-MYC 
( Yamamoto et al., 2016 ). When implanted in mice, FT-t cells 
form tumors that accurately mimic genetic features of HGSOC 
( Basuli et al., 2017 ; Yamamoto et al., 2016 ), rendering it a useful 
test case for how the model might predict the response of HGSOC 
to ferroptosis inducers. In particular, this cell line has low p53 
(due to inactivation by SV40), high TFRC, and low ferroportin, 
thereby displaying a high iron retention phenotype ( Basuli et al., 
2017 ). We can therefore use our system to model this cell line by 
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Fig. 6. Ferroptosis model output with all combinations of input conditions, sorted by ferroptotic response, displaying low ferroptosis after erastin treatment. 
setting the input variables (p53, TFRC, ferroportin) = (low, high, 
low). We can then analyze the response of the simulated cell line 
to ferroptosis inducers as a function of the remaining two input 
variables ACSL4 and SCD1 ( Fig. 8 ). 
We observe that due to high TFRC and low Fptn, we have 
maximal LIP and ROS levels (while ROS can also be increased by 
feedback from LO • in lower iron conditions, an iron retention 
phenotype leads to maximal ROS in our model). Due to the low 
p53, we have intermediate ALOX15: while ALOX15 is boosted 
by p53 activity, lack of p53 does not completely abrogate its 
expression and function. Even though p53 activity is low, due to 
the high iron, these cells are primed to undergo ferroptosis in the 
right conditions. 
If SCD1 activity is low, there are few MUFAs to inhibit LPCAT3, 
and directly inhibit PUFA incorporation into phospholipids. There- 
fore, LH-P levels are completely determined by ACSL4 activity, and 
LOOH is proportional to LH-P due to the high ROS. Thus, these cells 
will undergo ferroptosis upon inhibition of GPX4 activity if enough 
ACSL4 is present. If SCD1 activity is intermediate, there is partial 
inhibition of LPCAT3 and PUFA incorporation into phospholipids, 
evidenced by lower LH-P even at high ACSL4. Cells still respond to 
ferroptotic agents in the presence of ACSL4, but cannot maximize 
a ferroptotic response. Under conditions of high SCD1 activity, 
there is low LH-P due to MUFA-mediated inhibition of PUFA 
incorporation into phospholipids. Therefore, there is no substrate 
for ferroptosis to be initiated upon addition of ferroptotic agent. 
Overall, the model predicts that in the genetic background of 
FT-t cells, SCD1 knock-out will increase sensitivity to ferroptosis, 
but a double-knockout of ACSL4 and SCD1 will prevent this SCD1- 
knockout induced increase ( Fig. 8 ). To note, such a prediction is 
not possible using a static model, due to the complexity of inter- 
actions between the input parameters and model variables. For 
example, one can observe input parameter combinations where a 
low SCD1 and high ACSL4 background will not increase ferroptosis 
sensitivity ( Fig. 6 ). 
To test these predictions experimentally, we first ascertained 
the level of ACSL4 and SCD1 in FT-t cells in comparison to FT 
(primary fallopian tube stem cells) and FT-i (FT cells that have 
been immortalized but not transformed). We observed that both 
ACSL4 and SCD1 mRNA were elevated in FT-t in comparison to FT 
(Supplementary Figure 3), indicating that both of these genes are 
highly expressed in the model ovarian cancer stem cell line. Next, 
we knocked-down SCD1, ACSL4 , or both genes using siRNA pools 
and assayed cell viability following treatment with the ferroptosis 
inducer RSL3. A knock down of SCD1 and/or ACSL4 corresponds to 
setting the respective input parameter to ‘low’ in the model with 
other parameters maintained as discussed previously ( Fig. 8 ). 
The results of this experiment are shown in Fig. 9 . As seen 
in Fig. 9 a, knockdown of SCD1 was successful, resulting in an 
approximately 80% decrease in levels of SCD1 mRNA. Similarly, 
knockdown of ACSL4 resulted in an 80% decrease in levels of ACSL4 
when compared to a non-targeting control ( Fig. 9 b). Somewhat 
unexpectedly, knockdown of SCD1 slightly elevated ACSL4 mRNA 
( Fig. 9 b) and conversely, knockdown of ACSL4 elevated levels of 
SCD1 mRNA ( Fig. 9 a) above that of controls. We currently have no 
explanation for this apparent crosstalk, which to our knowledge 
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Fig. 7. A cellular algorithm for ferroptosis sensitivity. Provided known values of input variables (in blue), one can follow the algorithm to understand how a cell will ‘decide’ 
whether to undergo spontaneous or drug-induced ferroptosis. This algorithm provides a rule-based summary of the model steady state outcomes. 
has not been previously reported and merits further investigation. 
Nevertheless, as expected, levels of both mRNAs remained low 
when both were knocked down together ( Fig. 9 a,b). 
The successful knockdown of SCD1 and ACSL4 enabled us to 
test the effect of both single and double knockdowns on sensitiv- 
ity to ferroptosis. As shown in Fig. 9 c, control cells were sensitive 
to the ferroptosis inducer RSL3, exhibiting an approximately 20% 
decrease in viability. Sensitivity was dramatically enhanced (to ap- 
proximately 80%) when SCD1 was knocked down, consistent with 
model predictions and with a role of SCD1 as a cytoprotective pro- 
tein ( Tesfay et al., 2019 ). However, as predicted by the model, this 
enhanced cytotoxicity was blocked in cells in which ACSL4 was si- 
multaneously reduced ( Fig. 9 c, compare yellow bar to black bar in 
the central panel). Concurrent treatment of cells with the ferrop- 
tosis inducer RSL3 and the ferroptosis inhibitor ferrostatin blocked 
cell death in all cases ( Fig. 9 c), demonstrating that effects on cell 
viability were attributable to the process of ferroptosis and not to 
another cell death mechanism. Further, staining with trypan blue, 
which directly stains dead cells (as opposed to the calcein stain- 
ing shown in Fig. 9 c, which stains living cells, with death being 
inferred from a reduction in viability) confirmed that knockdown 
of SCD1 only increases cell death in a genetic background in which 
ACSL4 has not been simultaneously reduced ( Fig. 9 d). Collectively, 
these data demonstrate that our systems-level model can accu- 
rately predict sensitivity to ferroptosis induction as an outcome 
of the activity of multiple components of the ferroptotic induction 
cascade. 
3. Discussion 
Ferroptosis is a recently-described mode of cell death that is 
distinct from other known cell death pathways. The discovery 
of ferroptosis has engendered wide-spread interest in the de- 
velopment of anti-cancer drugs that induce this mechanism of 
cell death ( Stockwell et al., 2017 ). Although such drugs currently 
remain in a developmental stage, the complexity of the ferrop- 
totic process has made it clear that the successful deployment 
of ferroptosis-inducing agents will ultimately require an under- 
standing of how multiple parameters interact to dictate ferroptosis 
sensitivity or resistance in individual tumors. 
In this work, we develop a dynamic multistate discrete model 
of the pathways underlying the ferroptotic process in order to 
achieve a systems-level understanding of cellular susceptibility to 
ferroptosis. We show that the model behaves in a manner that is 
consistent with experimental observations. The model has allowed 
us to explore global properties of ferroptosis susceptibility. Im- 
portantly, we show that a cell’s sensitivity to ferroptotic inducers 
is a product of several interacting pathways, including PUFA-CoA 
synthesis and incorporation into phospholipids, and the balance 
between pro- and anti-oxidant species. 
More broadly, we show how different combinations of input 
variables (ACSL4, SCD1, Fptn, TFRC, and p53) alter ferroptosis sen- 
sitivity and obtain conclusions regarding the molecular profiles of 
these agents that can promote or inhibit sensitivity to ferroptosis 
induction ( Figs. 4–8 ). For example, high ACSL4 and low SCD1 
are necessary, but not sufficient, in our model to promote high 
ferroptosis sensitivity ( Fig. 5 ). Conversely, a combination of param- 
eters that minimizes production of LOOH - the first step in the 
lipid peroxidation pathway, will desensitize the cell to ferroptosis 
agents. As can be observed in Fig. 6 , there are many combinations 
of input variables that will lead to this result, indicating that 
ferroptosis sensitivity is a systems-level process, and thus that 
predicting ferroptosis sensitivity may ultimately require a gene- 
or protein- signature approach in a patient setting. To this end, 
we use the model framework and simulation results to derive a 
cellular algorithm for ferroptosis sensitivity given known values of 
input parameters ( Fig. 7 ). 
By simultaneously modeling the expression of multiple genes, 
our model was able to expand and clarify observations in the 
literature. ACSL4 has previously been shown to enhance sensitivity 
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Fig. 8. Modeling ferroptosis sensitivity in FT-t cells. Ovarian cancer stem cell line FT-t has low p53, high TFRC, and low Fptn. We consider the sensitivity of FT-t cells to 
erastin under varying SCD and ACSL4. The relationship between conditions experimentally tested and modeled is shown on the right-hand side. For example, the first row 
shows input conditions identical to the control FT-t row, except the input parameter SCD1 is set to low, which corresponds to a knock down of SCD1 in FT-t cells. 
to ferroptosis inducers ( Doll et al., 2017 ). Indeed, when simulating 
ACSL4 knockdown, we observe that response to RSL3 is inhibited 
( Fig. 3 ). Nevertheless, our systems-level approach predicted that 
there exist conditions of SCD1 and other major players in the 
ferroptotic cascade that render a cell unresponsive to ferroptotic 
induction despite high levels of ACSL4 ( Figs. 4–8 ). 
We used an ovarian cancer stem cell model to test this predic- 
tion, since effective treatments for ovarian cancer remain limited, 
and ferroptosis inducers may ultimately offer a therapeutic option 
in this disease. The model we selected exhibits a gene expression 
pattern that is generally concordant with that observed in ovarian 
tumors. In particular, using conditions pertinent to FT-t ovarian 
cancer stem cells ( Yamamoto et al., 2016 ) (setting Fptn, TFRC, 
and p53 to ‘low’, ‘high’, and ‘low’, respectively), the mathematical 
model predicted that under conditions of high SCD1, ACSL4 would 
be unable to exert this sensitizing effect ( Fig. 8 ). This prediction 
was validated experimentally ( Fig. 9 ). These results are consis- 
tent with recent observations implicating SCD1 as an inhibitor 
of ferroptosis ( Tesfay et al., 2019 ), and the demonstration that 
its products (MUFAs) promote ferroptosis resistance ( Magtanong 
et al., 2018 ); further, work from our laboratory has recently 
shown that prolonged inhibition of SCD1 can trigger cell death 
( Tesfay et al., 2019 ). Although this is somewhat surprising, given 
the ability of cells to take up MUFAs from exogenous sources 
( Kamphorst et al., 2013 ), a number of papers have similarly 
demonstrated that sustained inhibition of SCD1 induces cell death 
( Li et al., 2018 ; Leung and Kim, 2013 ; Mason et al., 2012 ; Minville- 
Walz et al., 2010 ; Hess et al., 2010 ). In the experiment shown 
in Fig. 9 , we deliberately selected conditions under which the 
effects of SCD1 inhibition were modest, in order to focus on the 
combined influence of SCD1 and ACSL4 on the response of cells to 
ferroptosis. This experimental strategy successfully illustrated the 
interdependence of SCD1 and ACSL4 predicted by the model. 
This example illustrates how intergenetic interactions can 
affect biological response in ways that are not inherently intuitive, 
and highlights the need for modeling to accurately capture the 
multiple variables that ultimately dictate biological response. In- 
terpreted in the context of patient response to therapy, our results 
suggest that modeling approaches that incorporate the expression 
of multiple genes will ultimately be required to successfully tailor 
therapy to individual patients to realize “precision medicine”. 
As our understanding of ferroptosis becomes more nuanced, it 
will become increasingly essential to use modeling to predict the 
combined contribution of multiple genes and pathways to ultimate 
cellular response, and to expand the model both within the core 
pathways of lipid peroxidation, and to additional pathways. Going 
forward, our model can serve as a framework for the addition of 
such new variables and pathways, which will ultimately improve 
the precision with which ferroptosis sensitivity can be predicted. 
For example, it has been suggested that iron concentration may 
impact the activity of iron-binding proteins involved in ferroptosis 
(e.g. ALOX15, SCD1) ( Dixon and Stockwell, 2014 ; Konstorum et al., 
2018 ), which may represent an additional layer of iron-mediated 
regulation of ferroptosis. Proteins that release or redistribute 
iron intracellularly ( Torti and Torti, 2013 ; Torti et al., 2018 ; 
Chifman et al., 2014 ; Hower et al., 2009 ) may also impinge on 
ferroptosis. For example, HO-1, an enzyme that degrades heme and 
is induced as part of an antioxidant response mediated by Nrf2, 
contributes to ferroptosis in several different contexts ( Fang et al., 
2019 ; Hassannia et al., 2018 ; Kwon et al., 2015 ). Further, feedback 
loops that redistribute intracellular iron, such as the release of 
iron from degradation of ferritin in the authophagolysosome ( Hou 
et al., 2016 ; Sui et al., 2019 ), also impact the ferroptotic cascade. 
Expansion or a focus of the model to intracellular iron distribution 
could yield rich insights into the contribution of intracellular iron 
distribution to ferroptosis. Additional contributors to ferroptosis 
that may ultimately factor into the model include the MAP kinase 
pathway, which plays a complex but as yet incompletely under- 
stood role in ferroptosis ( Xie et al., 2016 ), as well as two recently- 
described modulators of ferroptosis, AMPK ( Lee et al., 2020 ) 
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Fig. 9. FT-t cells were transfected with siRNA targeted to SCD1 (siSCD1), ACSL4 (siACSL4), non-targeting siRNA (siNTC) or siRNA targeted to both SCD1 and ACSL4 
(siSCD1 + siACSL4) for 48 h. a) Levels of SCD1 mRNA following knockdown of SCD1 and ACSL4 individually or together was Quantified by qRT-PCR. b) Levels of ACSL4 mRNA 
following knockdown of SCD1 and ACSL4 individually or together was quantified by qRT-PCR. c) Cells were treated with 0.5 to 2 μM RSL3 in the presence or absence of 
2 μM ferrostatin-1 for 24 h to assess sensitivity to ferroptosis. Cell viability was measured using calcein-AM. ∗∗p < 3.6E-29 (siNTC vs siSCD1 and siSCD1 vs siSCD1 + siACSL4) 
d) Cell death was determined using Trypan-blue exclusion. UNT, untreated controls. ∗p < 2.4E-02 (siNTC vs siSCD1 and siSCD1 vs siSCD1 + siACSL4). Represented are means 
and standard deviations of three independent experiments, each performed using eight technical replicates per point. 
and FSP1 ( Doll et al., 2019 ; Bersuker et al., 2019 ). Finally, a 
more in-depth modeling study of the complex contribution of 
p53 to ferroptosis may help to resolve potentially conflicting 
experimental results, which have demonstrated both pro- and 
anti-ferroptotic effects of p53 (for examples, see ( Magtanong et 
al., 2018 ; Jiang et al., 2015 ; Xie et al., 2017 )). Our model indicates 
that low/medium levels of p53 are necessary, but not sufficient, 
to induce ferroptosis, suggesting that other factors may impinge 
on p53 to drive final cellular outcome. A detailed, kinetic study 
of wildtype as well as mutant p53 and their effects in different 
cellular contexts may be required to clarify the full range of roles 
that p53 can play in ferroptosis. Nevertheless, at present our 
model contains sufficient critical players and interactions to shed 
light on the processes regulating lipid peroxidation mechanisms 
leading to ferroptosis. If properly adjusted to cell line or patient 
data, the model could be used in the future to predict sensitivity 
to pro-ferroptotic therapy and/or to optimize combinatorial effects 
of ferroptotic agents with other anti-cancer agents. 
4. Methods 
4.1. A stochastic multistate discrete modeling framework 
The mathematical model consists of five external inputs: ACSL4, 
SCD1 , ferroportin ( Fptn ), TFRC , and p53 and eleven variables (MUFA, 
PUFAc, LPCAT3, LHP, ALOX15, ROS, SLC7A11, GPX4, LOOH, LOr, LIP ), 
where PUFAc represents PUFA-CoA, LHP represents LH-P, and LOr 
represents the radical LO •. We represent the system with a state 
vector at discrete time t as 
x ( t ) = ( x 1 ( t ) , x 2 ( t ) , . . . , x 10 ( t ) , x 11 ( t ) ) 
= ( MU F A ( t ) , P U F Ac ( t ) , . . . , LOOH ( t ) , LOr ( t ) ) , 
where x I ∈ { 0 , 1 , 2 } for all x i ∈ x . At each time step, the state 
vector is updated as follows, 
x ( t + 1 ) = G ( x ( t ) ) = ( g i ( x ( t ) ) , p i ) , 
where g i ( x ( t) ) = c( x i (t) , f i ( x ( t ∗) ) . 
A. Konstorum, L. Tesfay and B.T. Paul et al. / Journal of Theoretical Biology 493 (2020) 110222 11 
Fig. 10. Transition tables for each modeled species in the multistate rule specification model of ferroptosis. 
For each variable x i , a transition table, f i , is specified ( Fig. 10 ). 
The transition table takes as input all variables that act on x i , and 
outputs a corresponding value of x i for the next time step. We 
take x ( t ∗) to represent a state of the system x such that a subset 
of x i ∈ x may have been updated. Then, g i imposes a continuity 
constraint, c , on the output f i ( x ( t 
∗)) which limits the jump size to 
one level for each x i . The probability P that x i ( t + 1 ) will update 
using g i is 
P ( x ( t + 1 ) ) = 
{
g i ( x ( t ) ) 
x i ( t ) 
is p i 
is 1 − p i . 
For all i , we take p i = 0.5 . An asynchronous update scheme 
is used at each time step, hence each variable is updated in a 
random order. The steady states of the system do not depend on 
the stochastic, continuous, or asynchronous update scheme in this 
framework ( Murrugarra et al., 2012 ). 
System behavior was simulated using Matlab R2017A. Choice of 
initial conditions of variables (aside from input variables, which are 
explored in Section 2.2.2) within a physiological range did not im- 
pact the steady states. Further details on the choice of initial con- 
ditions can be found in the Supplementary Information. 
4.2. Transition tables 
The transition tables for the multistate rule-specification model 
for ferroptosis are in Fig. 10 . We shall now motivate each entry. 
4.2.1. Monounsaturated fatty acids ( MUFA ) 
Production of the most abundant MUFAs in mammalian cells, 
oleic and palmitoleic acid, depends on desaturation of the satu- 
rated fatty acids (SFAs) stearic acid and palmitic acid, respectively, 
catalyzed by stearoyl-CoA desaturase ( SCD1 ) ( Paton and Ntambi, 
2009 ). In cancer cells, SCD1 is the main regulator of MUFA lev- 
els ( Igal, 2011 ). Nevertheless, MUFAs can also be imported into 
cells directly, which can be modeled by increasing MUFA levels 
independently of SFA levels and SCD1 activity. 
We assume that availability of SFAs is much greater than of 
MUFAs ( Harayama et al., 2014 ), and thus when SFAs are converted 
to MUFAs, qualitatively, SFA levels are not lowered in a propor- 
tional manner. 
4.2.2. Acetylated polyunsaturated fatty acids ( PUFA-CoA ) 
Membrane polyunsaturated fatty acids (PUFAs) are direct tar- 
gets for the ferroptotic cascade via their peroxidation ( Skouta et al., 
2014 ; Yang et al., 2016 ). In order for free fatty acids to be incor- 
porated into phospholipid membranes, they must be converted to 
acyl-CoA moieties by acyl-CoA synthetases. ACSL4 is an acyl-CoA 
synthetase with a strong preference for arachidonic acid and other 
PUFAs ( Kagan et al., 2017 ; Doll et al., 2017 ), and its activity has 
been found to be critical for sensitivity to ferroptosis inducers 
( Doll et al., 2017 ; Dixon et al., 2015 ). We model the effect of ACSL4 
as follows: at moderate levels of AA, moderate and high ACSL4 
result in moderate PUFA abundance, whereas at high AA, PUFA 
levels are directly related to ACSL4 levels. 
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4.2.3. LPCAT3 
Lysophosphatidylcholine Acyltransferase 3 (LPCAT3) is involved 
in the glycerophospholipid remodeling pathway (Lands’ cycle) 
which allows for the fatty acid composition of phospholipids to 
be altered. LPCAT3 shows highest acyltransferase activity toward 
PUFAs ( Shindou et al., 2009 ). Accordingly, it has been shown that 
LPCAT3 is essential for ferroptosis induced by inhibition of GPX4 
( Dixon et al., 2015 ). It has been observed that in SCD1 knock-down 
conditions, when MUFA levels are reduced, LPCAT3 levels are 
increased ( Ariyama et al., 2010 ). We thus model MUFAs as capable 
of partially inhibiting LPCAT3. 
4.2.4. PUFA-containing phospholipids ( LH-P ) 
Polyunsaturated fatty acids (PUFAs) are incorporated into phos- 
pholipids either during de novo biosynthesis (the Kennedy path- 
way) or maturation and remodeling (the Lands cycle). The acyl- 
transferase LPCAT3 preferentially adds PUFAs to phospholipids via 
the Lands cycle ( Shindou et al., 2009 ; Shindou and Shimizu, 2009 ; 
Hishikawa et al., 2008 ), and is critical for ferroptosis sensitivity, 
as discussed above. MUFAs can also inhibit PUFA incorporation 
into phospholipids via LPCAT3-independent mechanisms: Ariyama 
et al. ( Ariyama et al., 2010 ) showed that knockdown of SCD1 
(which would decrease MUFA levels) and LPCAT3 still resulted in 
an increase in phospholipid PUFA levels over control in HeLa cells. 
4.2.5. ALOX15 
ALOX15 is a non-heme iron-binding lipid peroxidating enzyme. 
It participates in reactions that lead to generation of lipid hy- 
droperoxides (LOOH) from unsaturated lipids (LH) (this activity is 
termed its lipoxygenase activity), as well as generation of peroxyl 
radicals (LO •) (among others) from lipid hydroperoxides (termed 
its lipohydroperoxidase activity) ( Ivanov et al., 2015 ; Girotti, 1998 ). 
The presence of ALOX15 has been found to be critical for ferroptosis 
sensitivity ( Dixon et al., 2015 ; Shintoku et al., 2017 ), and it has re- 
cently been shown that p53 can modulate ferroptotic response by 
increasing ALOX15 expression via the upregulation of SAT1 , which is 
proposed to act as a positive regulator of ALOX15 ( Ou et al., 2016 ). 
4.2.6. LIP 
While intracellular iron regulation involves complex pathways 
of transcriptional and post-translational modifications ( Torti and 
Torti, 2013 ), we consider a simple iron regulation model here, 
which only involves the iron import protein transferrin receptor 
1 (TFRC) and export protein ferroportin, both which are found in 
the cellular plasma membrane. Loosely bound intracellular iron, 
termed the labile iron pool (LIP) will occur with high TFRC and 
low ferroportin, and minimal LIP will occur in the complementary 
conditions. Attesting to the importance of these pathways in the 
pathophysiology of iron regulation, alterations in levels of these 
proteins are sufficient to affect tumor growth in animal models 
( Basuli et al., 2017 ; Pinnix et al., 2010 ) and to predict survival of 
cancer patients ( Basuli et al., 2017 ). Other regulators of LIP, such 
as the intracellular iron binding protein ferritin, or ferroportin 
inhibitor hepcidin, can be added to the model if considered im- 
portant with respect to iron-mediated ferroptosis sensitivity of the 
cell. 
4.2.7. ROS 
The ability of iron to mediate production of hydroxyl free radi- 
cals via the Fenton reaction, which can then trigger peroxidation of 
LH-P to LOOH and LOOH to LO • implicates the labile iron pool as 
an important contributor to the reactive oxygen species (ROSs) that 
participate in formation of lipid peroxides. Further, LO • can trigger 
further free-radical mediated lipid peroxidation ( Girotti, 1998 ). It 
has been demonstrated that the iron chelator deferoxamine (DFO) 
can inhibit ferroptosis ( Dixon et al., 2012 ), while the strength of 
the feedback of LO • on the peroxidation process and sensitivity to 
ferroptosis has not yet been investigated. While iron can play a role 
in ferroptosis that is independent of its free-radical activity ( Dixon 
and Stockwell, 2014 ), its contribution to the cellular ROS that is 
involved in lipid peroxidation is currently considered a significant 
contributor to ferroptosis sensitivity ( Stockwell et al., 2017 ), and 
thus its effect on boosting ROS in the model is considered to be 
stronger than that of LO •. 
4.2.8. SLC7A11 
SLC7A11 is a component of the cystine/glutamate antiporter 
system x c 
−, and is the target of the pro-ferroptotic drug erastin 
( Dixon et al., 2012 ). Additionally, the tumor suppressor p53 
has been shown to be a transcriptional regulator of SLC7A11 
( Jiang et al., 2015 ). Therefore, we model erastin as an inhibitor of 
SLC7A11 independent of p53 activity, and p53 as a partial activator 
of SLC7A11 via transcriptional modulation. 
4.2.9. GPX4 
Glutathione peroxidase 4 (GPX4) is a lipid hydroperoxide 
reducer within biological membranes, and interference with its 
activity will promote ferroptosis: indeed, RSL3 acts as a ferroptosis 
inducer by direct inhibition of GPX4 ( Yang et al., 2014 ). GPX4 
requires GSH for its reducing activity, which in turn requires 
cystine, thereby explaining how erastin can initiate ferroptosis: 
by inhibiting cystine uptake via SLC7A11, it limits production of 
GSH and therefore the substrate for GPX4 activity ( Stockwell et al., 
2017 ; Yang and Stockwell, 2016 ). We model GPX4 activity to be 
inhibited by RSL3, independent of SLC7A11 activity, and in absence 
of RSL3, its activity is set proportional to SLC7A11. 
4.2.10. LOOH and LO •
Lipid hydroperoxides (LOOH) and lipid radicals (LO •) are lipid 
peroxidation products that can be produced by ROS ( Girotti, 1998 ) 
and lipoxygenases (e.g. ALOX15) ( Ivanov et al., 2015 ) in a fashion 
independent of each others’ activity ( Feng and Stockwell, 2018 ). 
The anti-oxidant activity of GPX4 is at the level of LOOH, which 
can be converted to LOH in the presence of GPX4 ( Girotti, 1998 ). 
We thus model the generation of LOOH as a function of ROS and 
ALOX15 activity on the substrate LH-P. Generation of LO • is mod- 
eled in a similar fashion, where the substrate is now LOOH and 
GPX4 can mitigate the pro-oxidant effect of ROS and ALOX15. We 
consider each of these reactions to occur on a fraction of available 
substrate – therefore generation of LOOH does not deplete LH-P 
in a 1–1 fashion, but may be limited by limited availability of 
LH-P (and a similar consideration holds for generation of LO •). 
Since the presence of lipid radicals is considered to be the ini- 
tiator of ferroptotic processes ( Stockwell et al., 2017 ; Yang and 
Stockwell, 2016 ; Yang et al., 2016 ), we consider LO • as a proxy for 
ferroptosis in our model. 
4.2.11. Auxiliary functions: additive(x,y) and not(x) 
The additive(x,y) function represents the symmetric, additive ef- 
fect of two variables (x,y) on a variable z , and can be represented 
with the following algorithm: 
z = ad d iti v e ( x, y ) { 
su m xy = x + y 
if su m xy ≥ 3 : z = 2 
else if su m xy == 2 : z = 1 
else : z = 0 } 
The second auxiliary function, not(x) , represents the action of 
an inhibitor x on y . 
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4.3. In vitro experimental system 
Cell culture . FT, FT-i and FT-t cells (described in ( Basuli et al., 
2017 ; Yamamoto et al., 2016 )) were cultured in DMEM (Gibco) 
containing 10% FBS (Gemini Bio-Products). Cells were passaged 
less than five times before use for experiments. All cells were 
maintained at 37 °C in a humidified incubator at 5% CO 2 . 
Real-time qRTPCR . 200 ng of RNA was reverse transcribed in a 
total volume of 50 μl using a reverse transcription reagents kit 
(Applied Biosystems). To make a standard curve, serial dilutions of 
RNA from one sample were added to the RT reaction. Aliquots (2 
μl) of cDNA were added to a 18 μl reaction mixture containing 
10 μl of 2 × SYBR® Green PCR Master Mix (BioRad) and 400 nm 
primers. Absence of DNA contamination was confirmed by per- 
forming PCR from cDNA without reverse transcriptase. Primers 
used were: 
- human SCD1 forward: AAACCTGGCTTGCTGATG 
- human SCD1 reverse: GGGGGCTAATGTTCTTGTCA 
- human ACSL4 forward: CATCCCTGGAGCAGATACTCT 
- human ACSL4 reverse: TCACTTAGGATTTCCCTGGTCC 
- human β-Actin forward: TTG CCG ACA GGA TGC AGA AGG A 
- human β-Actin reverse: AGG TGG ACA GCG AGG CCA GGA T 
Cell viability . 50 0 0 FT-t cells were transfected with siRNA for 
48 h. Afterwards, cells were treated with 0.5 μM of RSL3 (Sel- 
leckchem) in presence or absence of 2 μM ferrostatin-1 (Sell- 
eckchem) for 24 h. Cell viability was assessed using calcein-AM 
(Millipore), a fluorescent dye that stains living cells. Briefly, cells 
plated in 96 well black-walled plates (Corning) were incubated 
with 2 uM calcein-AM for 30 min at 37 °C in a humidified incu- 
bator at 5% CO 2 . Fluorescence was measured in a fluorescent plate 
reader (BioTek, Synergy2) using 480/520 nm excitation/emission 
( Stoddart, 2011 ). 
Trypan-blue exclusion assay . 1 × 10 6 FT-t cells were transfected 
with siRNA for 48 h. Afterwards, cells were treated with 0.5 to 
2 μM of RSL3 (Selleckchem) for 24 hrs. Cells were counted follow- 
ing staining with 0.4% Trypan-blue (Invitrogen), a dye that stains 
dead cells but is excluded by living cells. The percentage of stained 
cells as a fraction of the total number of cells was quantified using 
a hemocytometer ( Stoddart, 2011 ). 
siRNA knock-down experiments . All reagents were obtained from 
GE Dharmacon (Lafayette, CO, USA). 12 ng of ON-TARGETplus Hu- 
man SCD1 siRNA (L-0 05,061–0 0–0 010), ON-TARGETplus Human 
ACSL4 (2182) siRNA (L-0 09,364–0 0–0 0 05) and siNTC (cat#: d - 
001,810–10–05) were used for knockdown experiments. Transfec- 
tions were performed according to the manufacturer’s recommen- 
dations using Dharmafect #1 transfection reagent (cat: T-2001). 
Knockdown efficiencies were confirmed at the time of harvest by 
RT-qPCR. 
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